British In Vitro Diagnostics Association welcomes first strategy for Medical Technology from the Government
The Department of Health and Social Care published the first strategy for medical technology today. The British In Vitro Diagnostics Association (BIVDA) welcomes this as another step forward to achieving the wider use of essential diagnostic tests and enabling technology which can really support better healthcare for patients and save resource for the NHS.
BIVDA’s Chief Executive, Doris-Ann Williams MBE said “BIVDA saw the creation of the MedTech Directorate as a valuable and pragmatic step for our industry, in vitro diagnostics (IVDs) are a crucial part of the much wider MedTech sector".
"We welcome the Medical Technology Strategy which is comprehensive and covers all the aspects that our industry faces in delivering world class diagnostic testing to the NHS, including market access and regulation".
“We are committed to working closely with the MedTech Directorate to support the delivery of this Strategy".
IVDs deliver essential information used in diagnosing, monitoring and managing health. They are also essential for screening for disease, both in patients and to ensure the safety of the blood supply and play an increasing role in prevention of ill health and early diagnosis of diseases such as cancer.
BIVDA, is the National Industry Association for IVDs, representing 240 companies focussed on developing, manufacturing and distributing IVD tests and technology.
For more information or for any press enquiries, please contact: BIVDA Press Office